Zopiclone (Imovane)

Zopiclone (brand names Imovane, Zimovane, Ximovan) is the first cyclopyrrolone and belongs to the Z-drugs: non-benzodiazepine hypnotics that are chemically unrelated to benzodiazepines but hit an identical target. The label "non-benzodiazepine" is misleading here, because it suggests a more favorable safety profile than the data support.

This substance has the highest dependence potential in the entire TPD catalog. Tolerance, physical dependence and withdrawal are documented at normal doses and within a few weeks. International guidelines therefore cap use at 2 to 4 weeks including tapering. That is the ceiling, not a cautious suggestion.

This information is for research and educational purposes only. No medical advice.

Zopiclone binds at the benzodiazepine binding site of the GABA-A receptor complex and acts there as a positive allosteric modulator: it does not open the chloride channel itself but amplifies the action of the body's own GABA. The net effect is broad dampening of neuronal activity with a sedative emphasis.

The decisive difference from zolpidem lies in selectivity. Zolpidem prefers alpha-1 containing receptor subtypes, which focuses the effect more narrowly on sedation. Zopiclone is non-selective across subtypes and therefore brings anxiolytic, muscle-relaxant and anticonvulsant components with it. That breadth is exactly why the dependence and side effect profile sits considerably closer to the benzodiazepines than the class name suggests.

• Bioavailability: roughly 75-80 percent oral.
• Onset: typically within 30 minutes, peak levels after 1.5-2 hours.
• Half-life: about 5 hours, rising to 7 hours or more in older individuals and impaired liver function.
• Metabolism: via CYP3A4 and CYP2C8. Eszopiclone is the S-enantiomer of the same molecule.

This is the core of this entry and the reason zopiclone has to be handled differently from the rest of the catalog.

• Dependence: in a national survey of more than 1000 people who had used benzodiazepines or Z-drugs for at least three months, 45 percent met the formal DSM dependence criteria. Pre-existing addiction disorders or psychiatric diagnoses raise that risk further and substantially.
• Tolerance within 2-4 weeks: the sleep-inducing effect wanes under daily use. The typical documented course is a creeping dose increase to hold the same effect - precisely the path into dependence. The correct response to a fading effect is stopping, not increasing.
• Rebound insomnia: after discontinuation, sleep can temporarily be worse than before the first dose. This is regularly misread as "the sleep problem is back" and drives resumption. It is part of the withdrawal reaction and subsides.
• Withdrawal: after prolonged use, anxiety, agitation, tremor, sweating, palpitations and in severe cases seizures are documented. Abrupt discontinuation after weeks of daily use is dangerous - tapering belongs in medical hands.

Practical consequence: intermittent use on 2-3 nights per week is clearly preferable to use every night, because tolerance builds considerably more slowly that way.

Two risks stand on their own because they are not dose-dependent and occur on first, normally dosed use as well.

Complex sleep behaviors. Sleepwalking, cooking, eating, phoning and driving while asleep - with no recollection afterward. In 2019 the FDA issued a Boxed Warning for the entire Z-drug class because of these events. The underlying review of the adverse event database covered 66 cases with serious injuries, including 20 deaths: carbon monoxide poisoning, drowning, hypothermia, third-degree burns, traffic collisions and suicides. A single such episode is treated as a contraindication to any further use. That anterograde amnesia hides these episodes from the affected person does not make them more harmless, only harder to detect.

Combination with alcohol or opioids. Potentially fatal. The respiratory depressant effects add up and alcohol amplifies sedation on top. The same applies to benzodiazepines, gabapentinoids, sedating antihistamines and GHB. There is no safe amount and no safe interval within the same night. This combination is the primary mechanism by which Z-drugs appear in mortality statistics.

Efficacy is not in dispute. Hajak's review (Drug Safety 1999) of 15 years of clinical use shows that 7.5mg zopiclone improves sleep latency and total sleep time at least as well as classic benzodiazepine hypnotics, with less residual sedation than the long-acting members of that class. The same paper states explicitly that zopiclone is intended for short-term use and should not be used for more than 4 weeks.

The safety picture has sharpened since then. Older work from the 1990s rated the dependence risk as low. Newer data contradict that clearly: the survey by Victorri-Vigneau et al. (2020) found DSM dependence criteria met in 45 percent of long-term users. The meta-analysis by Verster et al. (2006) showed that zopiclone 7.5mg significantly impairs driving performance in the standardized on-the-road test the morning after evening dosing, while zolpidem 10mg and zaleplon 10mg did not in the same analyses. And the FDA review by Harbourt et al. (2020) led to the Boxed Warning over complex sleep behaviors with serious injuries and deaths.

In short: the substance reliably does what it is meant to do - and the price for that is just as reliably documented in the data.

• Bitter metallic taste: the characteristic and most common adverse effect, occasionally persisting for hours. Harmless, but a reliable identifying feature.
• Next-day residual sedation: grogginess, slowed reactions, measurable driving impairment in the morning.
• Anterograde amnesia: memory gaps for the period after dosing, dose-dependent.
• Falls and fractures: cohort studies document a dose-dependent increase in fracture risk, particularly in older users. Getting up at night under residual sedation is the typical mechanism.
• Dizziness, dry mouth, headache: common, mostly mild accompanying effects.
• Paradoxical reactions: agitation, irritability, aggression or nightmares instead of sedation - rare, but documented.
• CYP3A4 interactions: ketoconazole, erythromycin, clarithromycin and ritonavir clearly raise levels and sedation. Rifampicin lowers them.

Store dry, at room temperature and protected from light. Out of reach of children - zopiclone is strongly sedating even in small amounts. The 100-tablet bottle corresponds to a large multiple of the guideline-conform duration of use and is a stock quantity, not a usage instruction.